Animal-Assisted Interactions in Improving Quality of Life in Children with Advanced, Relapsed, or Refractory Cancer and Their Parents
This trial studies how well animal-assisted interactions work in improving quality of life in children with cancer that has spread extensively to other anatomic sites or is no longer responding to treatment, has come back, or does not respond to treatment, and their parents. Having animal-assisted therapy (AAT) visits on a routine basis with a trained animal-handler and his / her dog may help to make the cancer treatment process less stressful for children and their parents.
- CHILDREN: Ages of 3-17 years
- CHILDREN: Diagnosed with advanced cancer as defined by any stage of relapsed or refractory cancer in medical record
- CHILDREN: Able to understand English or Spanish to complete consents and surveys
- CAREGIVERS: Primary caregiver as determined by parent who brings child to > 50% of their clinic visits
- CAREGIVERS: Able to understand English or Spanish to complete consents and surveys
- A reported fear of or allergies to canines or cognitive impairment
Locations & Contacts
Contact: Mary Jo Gilmer
Trial Objectives and Outline
I. Examine feasibility of animal-assisted interactions (AAI) sessions for children with a life-threatening condition (LTC) and primary caregiver, specifically to identify and document necessary modifications for a safe and feasible intervention, obtain recruitment estimates and determine potential recruitment barriers, evaluate elements of implementation fidelity (design, training, delivery/receipt of treatment, enactment), and verify safety.
II. Determine the preliminary efficacy of AAI sessions for children with a LTC for the outcomes of health-related quality of life (HRQoL), stress, and anxiety, primary caregivers of children with a LTC for the outcomes of stress and anxiety.
OUTLINE: Participants are randomized to 1 of 2 groups.
GROUP I: Participants receive AAI over 15 minutes during each potentially anxiety-producing visit to the hospital or clinic.
GROUP II: Participants receive usual care.
Trial Phase & Type
No phase specified
Vanderbilt University / Ingram Cancer Center
Mary Jo Gilmer
Secondary IDs NCI-2018-03164
Clinicaltrials.gov ID NCT03765099